Mark Massaro, an analyst from BTIG, reiterated the Buy rating on MaxCyte (MXCT – Research Report). The associated price target was lowered to $5.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Mark Massaro’s rating is based on several key aspects of MaxCyte’s recent performance and strategic positioning. The company delivered better-than-expected results in its milestone and royalty segment for the first quarter, despite a slight decline in core revenue growth. This performance, coupled with the reaffirmation of its 2025 revenue guidance, suggests a stable outlook for the company.
Additionally, MaxCyte’s acquisition of SeQure Dx, a gene editing safety analytics company, is progressing well and is expected to enhance the company’s service offerings. The acquisition was achieved with a modest cash outlay, indicating effective capital management. Furthermore, MaxCyte’s strong balance sheet, with substantial cash reserves and no debt, positions it well for future growth opportunities. These factors collectively underpin Massaro’s Buy rating for MaxCyte’s stock.
According to TipRanks, Massaro is an analyst with an average return of -7.8% and a 29.92% success rate. Massaro covers the Healthcare sector, focusing on stocks such as NeoGenomics, Adaptive Biotechnologies, and GeneDx Holdings.